The UK has banned puberty blockers for children under 18, joining other European countries in limiting access to this treatment for transgender youth. This decision follows a temporary ban and reflects ongoing medical debates about the appropriateness and effects of such treatments. The UK government commissioned a review that found weak evidence regarding the impact of puberty blockers on mental health and development. Other European countries are also reevaluating their approaches, with some prioritizing counseling over medical interventions. The discussion emphasizes the need for more research and a holistic approach to care for gender-questioning youth.